HCM
CABA icon

Heights Capital Management’s Cabaletta Bio CABA Stock Holding History

Heights Capital Management’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,084,202
Closed -$4.88M – 197
2025
Q3 		$4.88M Sell
2,084,202
-1,059,904
-34% -$1.82M 1.39% 15
2025
Q2 		$4.78M Buy
+3,144,106
New +$4.9M 1.28% 18

Other funds holding CABA

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Superstring Capital Management New York $140M AUM 323.19% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Heights Capital Management's CABA Position: Q4 2025 in Review

Heights Capital Management sold out of Cabaletta Bio (CABA) in Q4 2025, closing a stake of 2,084,202 shares — an estimated $4.88M sold.

Heights Capital Management first reported a position in CABA in Q2 2025 and held it in 2 quarters. The position peaked at $4.88M in Q3 2025. 95 funds tracked by Wall St. Rank hold CABA as of Q4 2025.

  • Heights Capital Management reported no remaining Cabaletta Bio position as of Q4 2025 after selling out during the quarter.
  • Heights Capital Management sold 2,084,202 Cabaletta Bio shares in Q4 2025, an estimated $4.88M.
  • Heights Capital Management first reported a position in Cabaletta Bio in Q2 2025 and held it in 2 quarters.
  • Heights Capital Management's Cabaletta Bio position peaked at $4.88M in Q3 2025.
  • 95 funds tracked by Wall St. Rank held Cabaletta Bio as of Q4 2025.

Based on Heights Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.